Relation between COPD severity and global cardiovascular risk in US adults

Chest

Volumn 142, Issue 5, 2012, Pages 1118-1125

  Lee, Hwa Mu ^a   Lee, Janet ^a   Lee, Katherine ^a   Luo, Yanting ^a   Sin, Don D ^b   Wong, Nathan D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; UNITED STATES;

EID: 84868612017     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2421     Document Type: Article

References (27)

1. Petty TL. Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. Chest. 2000;117(5)(suppl 2):326S-331S. (Pubitemid 30314461)
2. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245-1257. (Pubitemid 44883863)
3. Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137-148.
4. World Health Organization. Chronic obstructive pulmonary disease (COPD) fact sheet. World Health Organization website. www.who.int/mediacentre/ factsheets/fs315/en/index.html. Published November 2011. Accessed March 13, 2012.
5. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Osterman MJ. Births: final data for 2008. Natl Vital Stat Rep. 2010;59(1):1, 3-71.
6. Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94(5):649-651. (Pubitemid 39165849)
7. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63-70. (Pubitemid 41783891)
8. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952-1959.
9. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753. (Pubitemid 351640675)
10. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20-24. (Pubitemid 38813447)
11. Whitemore AS, Perlin SA, DiCiccio Y. Chronic obstructive pulmonary disease in lifelong nonsmokers: results from NHANES. Am J Public Health. 1995;85(5):702-706.
12. Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med. 2002;22(1):42-48. (Pubitemid 34037011)
13. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
14. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187. (Pubitemid 29036522)
15. Third National Health and Nutrition Examination Survey III: Spirometry Procedure Manual. Centers for Disease Control website. http://www.cdc.gov/nchs/ data/nhanes/nhanes3/cdrom/nchs/manuals/spiro.pdf. Published 1988. Accessed March 1, 2010.
16. Hankinson JL, Crapo RO, Jensen RL. Spirometric reference values for the 6-s FVC maneuver. Chest. 2003;124(5):1805-1811. (Pubitemid 37433576)
17. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(suppl 5):121S-126S. (Pubitemid 34497328)
18. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11-21.
19. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at an increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-1519. (Pubitemid 36378490)
20. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012. (Pubitemid 38269277)
21. Lee HM, Le TV, Lopez VA, Wong ND. Association of C-reactive protein with reduced forced vital capacity in a nonsmoking U.S. population with metabolic syndrome and diabetes. Diabetes Care. 2008;31(10):2000-2002.
22. Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J. 2009;85(1006):414-421.
23. Mancini GBJ, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statin, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with COPD. Proc Am Coll Cardiol. 2006;47(12):2554-2560. (Pubitemid 43866389)
24. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279-283. (Pubitemid 46237383)
25. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006-1012. (Pubitemid 46608700)
26. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.
27. Forgarty AW, Jones S, Britton JR, Lewis, SA, McKeever TM. Systemic inflammation and decline in lung function in a gen eral population: a prospective study. Thorax. 2007;62(6):515-520. (Pubitemid 46910130)